相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi et al.
BLOOD (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
M. P. Kline et al.
LEUKEMIA (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
Patricia Perez-Galan et al.
BLOOD (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells
Camilla Stapnes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel et al.
CLINICAL CANCER RESEARCH (2007)
A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro
Kyoung Joon Oh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
A stapled BID BH3 helix directly binds and activates BAX
Loren D. Walensky et al.
MOLECULAR CELL (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo
Alex R. Shoemaker et al.
CANCER RESEARCH (2006)
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
OA O'Connor et al.
CLINICAL CANCER RESEARCH (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas
L Paoluzzi et al.
BIODRUGS (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Measurement of apoptosis of intact human islets by confocal optical sectioning and stereologic analysis of YO-PRO-1-stained islets
DJ Boffa et al.
TRANSPLANTATION (2005)
BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly
T Kuwana et al.
MOLECULAR CELL (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Cell death: Critical control points
NN Danial et al.
CELL (2004)
The Bcl-2 family: roles in cell survival and oncogenesis
S Cory et al.
ONCOGENE (2003)
Discovery, characterization, and structure - Activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins
S Kitada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai et al.
CANCER CELL (2002)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
A Degterev et al.
NATURE CELL BIOLOGY (2001)
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
JL Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
